These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19467899)

  • 1. Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha.
    Machado P; Santos A; Pereira C; Loureiro C; Silva J; Chieira C; Malcata A
    Joint Bone Spine; 2009 Oct; 76(5):508-13. PubMed ID: 19467899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
    Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
    Cuchacovich M; Soto L; Edwardes M; Gutierrez M; Llanos C; Pacheco D; Sabugo F; Alamo M; Fuentealba C; Villanueva L; Gatica H; Schiattino I; Salazaro L; Catalan D; Valenzuela O; Salazar-Onfray F; Aguillón JC
    Scand J Rheumatol; 2006; 35(6):435-40. PubMed ID: 17343250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Occupational therapy in rheumatoid arthritis: short term prospective study in patients treated with anti-TNF-alpha drugs].
    Pasqui F; Mastrodonato L; Ceccarelli F; Scrivo R; Magrini L; Riccieri V; Di Franco M; Gentili M; Valesini G; Spadaro A
    Reumatismo; 2006; 58(3):191-8. PubMed ID: 17013435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study.
    Peters MJ; Welsh P; McInnes IB; Wolbink G; Dijkmans BA; Sattar N; Nurmohamed MT
    Ann Rheum Dis; 2010 Jul; 69(7):1281-5. PubMed ID: 19934107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.
    Wijbrandts CA; van Leuven SI; Boom HD; Gerlag DM; Stroes EG; Kastelein JJ; Tak PP
    Ann Rheum Dis; 2009 Aug; 68(8):1316-21. PubMed ID: 18723565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and clinical effects of anti-TNFalpha treatment.
    Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
    Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is the response to anti-TNFalpha treatment influenced by the presence of IgM rheumatoid factor, in Rheumatoid Arthritis patients?].
    Mourão AF; Santos FP; Falcão S; Barros R; Pinto TL; Mendes A; Castelão W; Nero P; Fonseca JE; Matos AA; Branco JC
    Acta Reumatol Port; 2008; 33(4):430-4. PubMed ID: 19078861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
    Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
    Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
    Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
    Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
    Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
    Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients.
    Sidiropoulos PI; Siakka P; Pagonidis K; Raptopoulou A; Kritikos H; Tsetis D; Boumpas DT
    Scand J Rheumatol; 2009; 38(1):6-10. PubMed ID: 18991190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.